Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Selenium and its compousends as perspektive drugs in onkology

Joint Event on 4th European Biopharma Congress & 6th International Conference and Exhibition on Pharmacology and Ethnopharmacology

Melnik Milan

Faculty of Medicine Comenius University in Bratislava, Slovakia

Posters & Accepted Abstracts: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X-C1-026

Abstract
In last years, hhere have been some notable developments as several areas of inorganic pharmaceutical that have potentially for ��? reacting importance for future medicial applications and reasearch. One of the highly significant developmeats in the field of oncology and hematology is the application role selenium compounds. Selenium ions play an important role in biological systems, and without their catalytic presence interrace or ultratrace amouts many essential co ��? factors for many biochemical reactions would endogenous antioxidant enzymes. Selenium is an essential component of several endogenous antioxidant enzymes. Selenium affects the transugtion of multiple defense and regair genes to protect against metal ��? induced pathologies. Selenium creates stable compleces a wide variety of organic molecules that canprovide required biological afinity and therapeutical activity veritable for tangeling specific locations in the body. The aim of this revier is a critical evalution of selenium complexes used for therapy or diagnosis of various diseases in oncology.
Biography
Top